[{"company":"Ligand Pharmaceuticals","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Enters into OmniAb\u00ae Platform License Agreement with Pandion Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ligand Pharmaceuticals"},{"company":"Ventus Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Uncloaks with $60M to Target the Innate immune System","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ventus Therapeutics"},{"company":"HotSpot Therapeutics","sponsor":"S.R. One","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"SR One fuels HotSpot's $65M B round to fund allosteric R&D","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"HotSpot Therapeutics"},{"company":"Dyno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Dyno Therapeutics"},{"company":"Quench Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Quench Bio"},{"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"SIGA Technologies"},{"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$414.0 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Deliveries of Oral TPOXX\u00ae to HHS Valued at Approximately $32 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"SIGA Technologies"},{"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$55.0 million","newsHeadline":"Dragonfly Therapeutics Announces Collaboration with BMS to Develop Novel Therapeutic Candidates for M.S and Neuro-inflammation Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Dragonfly Therapeutics"},{"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$40.0 million","newsHeadline":"Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Jnana Therapeutics"},{"company":"Ventus Therapeutics","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Therapeutics Closes $100 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ventus Therapeutics"},{"company":"TetraGenetics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"TetraGenetics"},{"company":"Lycia Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Lycia Therapeutics"},{"company":"IpiNovyx Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"IpiNovyx Bio"},{"company":"Mozart Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Mozart Therapeutics"}]
Details:
The company will use the Series A funds to progress its lead CD8 Treg Modulator into the clinic while also advancing additional programs generated from its novel platform.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
ARCH Venture Partners
Deal Size: $55.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
October 26, 2021
Details:
Proceeds from the financing will support the company’s continued advancement of its lead drug candidates toward first-in-human clinical studies, including submission of the company’s first investigational new drug (IND) application.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Viva BioInnovator
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Financing
October 05, 2021
Details:
Integrating TetraGenetics’ capabilities into AbCellera’s technology provides an optimized protein source for AbCellera’s antibody discovery. Together, these technologies have the potential to unlock the discovery of antibodies against validated and sought-after drug targets.
Lead Product(s):
Antibodies
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
AbCellera
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
September 13, 2021
Details:
The company’s lysosomal targeting chimeras, or LYTAC, platform can be extended to several therapeutic modalities, including antibodies and small molecules, with the potential to inhibit many targets.
Lead Product(s):
LYTAC-based Therapeutics
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Redmile Group
Deal Size: $70.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
September 09, 2021
Details:
Proceeds from the Series B will be used to advance Ventus’ pipeline of novel medicines to treat diseases in multiple therapeutic areas and expand platform capabilities.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
BVF Partners L.P
Deal Size: $100.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
April 08, 2021
Details:
Under the terms of the agreement, Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and commercialize exclusively.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
F. Hoffmann-La Roche
Deal Size: $1,040.0 million
Upfront Cash: $40.0 million
Deal Type: Collaboration
July 21, 2020
Details:
Under the agreement, Dragonfly will grant Bristol Myers Squibb the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary platform for multiple new targets.
Lead Product(s):
NK cell Engager Therapies
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Bristol Myers Squibb
Deal Size: Undisclosed
Upfront Cash: $55.0 million
Deal Type: Licensing Agreement
July 06, 2020
Details:
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the deliveries of oral TPOXX® (tecovirimat) to the U.S. Department of Health and Human Services (HHS).
Lead Product(s):
Tecovirimat
Therapeutic Area: Immunology
Product Name: Tpoxx
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
BARDA
Deal Size: $414.0 million
Upfront Cash: Undisclosed
Deal Type: Agreement
June 25, 2020
Details:
Funding will support work necessary to gain a potential label expansion from the U.S. FDA for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox.
Lead Product(s):
Tecovirimat
Therapeutic Area: Immunology
Product Name: Tpoxx
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
JPEO-CBRND
Deal Size: $23.0 million
Upfront Cash: Undisclosed
Deal Type: Funding
June 15, 2020
Details:
The Series B financing will support the advancement of HotSpot’s lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
S.R. One
Deal Size: $65.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
May 21, 2020
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
